Posted by Michael Wonder on 24 Nov 2020
NICE backs Braftovi for BRAF positive colorectal cancer
24 November 2020 - NICE has back Pierre Fabre’s Braftovi plus cetuximab for the treatment of BRAF positive metastatic colorectal cancer.
In September, NICE initially turned down Braftovi (encorafenib) after finding that the cost-effectiveness estimates were higher than what is normally considered value for money for the NHS.
